- Home
- ALLO vs NODK Comparison
ALLO vs NODK Comparison
Compare ALLO & NODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- NODK
- Stock Information
- Founded
- ALLO 2017
- NODK 1946
- Country
- ALLO United States
- NODK United States
- Employees
- ALLO N/A
- NODK N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- NODK Property-Casualty Insurers
- Sector
- ALLO Health Care
- NODK Finance
- Exchange
- ALLO Nasdaq
- NODK Nasdaq
- Market Cap
- ALLO 231.9M
- NODK 259.5M
- IPO Year
- ALLO 2018
- NODK 2017
- Fundamental
- Price
- ALLO $1.11
- NODK $13.40
- Analyst Decision
- ALLO Strong Buy
- NODK
- Analyst Count
- ALLO 10
- NODK 0
- Target Price
- ALLO $8.88
- NODK N/A
- AVG Volume (30 Days)
- ALLO 3.8M
- NODK 12.4K
- Earning Date
- ALLO 11-06-2025
- NODK 11-06-2025
- Dividend Yield
- ALLO N/A
- NODK N/A
- EPS Growth
- ALLO N/A
- NODK N/A
- EPS
- ALLO N/A
- NODK 0.07
- Revenue
- ALLO N/A
- NODK $310,389,000.00
- Revenue This Year
- ALLO N/A
- NODK N/A
- Revenue Next Year
- ALLO $100.00
- NODK N/A
- P/E Ratio
- ALLO N/A
- NODK $189.29
- Revenue Growth
- ALLO N/A
- NODK N/A
- 52 Week Low
- ALLO $0.86
- NODK $12.01
- 52 Week High
- ALLO $3.78
- NODK $17.24
- Technical
- Relative Strength Index (RSI)
- ALLO 44.66
- NODK 57.81
- Support Level
- ALLO $1.06
- NODK $12.85
- Resistance Level
- ALLO $1.18
- NODK $13.40
- Average True Range (ATR)
- ALLO 0.08
- NODK 0.31
- MACD
- ALLO 0.01
- NODK 0.07
- Stochastic Oscillator
- ALLO 31.25
- NODK 100.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.